Reducing Acute Kidney Injury Occurence by Administering Angiotensin II

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 27, 2021

Primary Completion Date

December 19, 2022

Study Completion Date

March 19, 2023

Conditions
Cardiac SurgeryVasoplegiaHyperreninemia
Interventions
DRUG

Angiotensin II

Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.

DRUG

Control

Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo

Trial Locations (1)

48149

University Hospital Muenster, Münster

Sponsors
All Listed Sponsors
collaborator

German Research Foundation

OTHER

lead

Universität Münster

OTHER